Shanghai Shyndec wins approval for pravastatin sodium tablets
Shanghai Shyndec Pharmaceutical (SSE: 600420) announced that its Pravastatin Sodium Tablets (10mg) have passed the generic drug consistency evaluation. The drug, used to treat hypercholesterolemia, achieved sales of RMB 924 million in public hospitals nationwide in 2023, with Shyndec's sales reaching RMB 105 million. With this approval, Shanghai Shyndec now has all three specifications (10mg, 20mg, 40mg) of Pravastatin Sodium Tablets passing the evaluation. Currently, other companies with approvals for Pravastatin Sodium Tablets (10mg) include Hainan Sino-American Pharmaceutical, Hangzhou Hanyu Pharmaceutical, and Chongqing Lummy Pharmaceutical. The company has invested approximately RMB 33.2365 million in the research and development of Pravastatin Sodium Tablets, including other specifications. The company cautions that drug sales are subject to industry policies and market conditions, advising investors to exercise caution.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Shyndec Pharmaceutical publishes news
Free account required • Unsubscribe anytime